Client(s):
Global Fund

Desk reviews and in-country evaluations of HIV, TB and malaria programs in Focused countries.
 

Value:
Undisclosed
Status:
Active
Location:

Evaluation of HIV, TB and malaria programs in Focused Countries

The Global Fund categorises the countries it supports into three groups: High Impact, Core, and Focused.  Each group of countries is now managed in a differentiated manner, with major resources allocated to the High Impact portfolios and streamlined processes put in place for management of investments in Focused portfolios. As of 2017, there are 25 High Impact countries, 30 Core countries and 68 Focused countries. The Global Fund has changed the way it evaluates its funded programs in Focused countries.

Want to work with us on these evaluations as a consultant? See our call for consultants at the bottom of this page.

The Global Fund has changed the way it evaluates its funded programs in Focused countries. The objectives of each evaluation are:

  • To evaluate, the extent to which and how, the Global Fund grants have helped enable Focussed countries to achieve a) the goals and objectives described in their national disease strategic plans and overall health sector strategy, and b) the goals and objectives agreed in the grant agreements
  • To evaluate the extent to which service delivery systems (health facility and community) deliver quality services
  • To evaluate the extent to which country data systems generate, report and use quality data
  • To evaluate the extent to which Global Fund investments have helped countries prepare financially and programmatically for a sustained response to the three diseases
  • To support countries to use the findings from the evaluations to help inform investment decisions and efforts to improve the quality, efficiency and sustainability of the response to the three diseases.

APMG Health has the global contract for these evaluations.

There are three levels of evaluation proposed, depending in disease burden and level of investment. In Type I countries, which have the largest relative disease burden and investment size among the Focused countries, the evaluations will cover the entire national program (or multiple relevant programs) in depth. Where possible, these evaluations will leverage and help strengthen existing national program review processes. In Type II countries, the evaluations will target program components directly supported by the Global Fund grants. In Type III countries, which have the smallest relative disease burden and investment size among the Focused countries, only secondary data analysis will be performed, without an additional in-country evaluation component.